The U.S. Centers for Disease Control and Prevention (CDC) has not found a link between heart inflammation and Covid-19 vaccines, the agency’s Director Rochelle Walensky said on April 27.

Inovio Pharmaceuticals said on April 23 the U.S. government had stopped funding for a late-stage study testing the company’s Covid-19 vaccine candidate, due to the increasing availability of authorized shots in the country.

The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration authorized the emergency use of the mRNA vaccine, BNT162b2, against Covid-19 in individuals 16 years of age or older.

Inovio Pharmaceuticals Inc. dosed the first participant in a mid-stage clinical trial testing the company’s Covid-19 vaccine candidate, INO-4800.

Inovio Pharmaceuticals Inc. received clearance from the U.S. health regulatory agency to begin a mid-stage study of the company’s Covid-19 vaccine candidate, the vaccine maker said.

U.S. coronavirus infections surged by at least 129,606, according to a Reuters tally, the third consecutive daily rise of more than 100,000 cases as a third wave of Covid-19 sweeps the United States.

With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.

Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).

23andMe announced that the company was laying off about 100 employees as sales were down, reflecting a shrinking market for DNA test kits to consumers.